1. Positron emission tomography combined with serum biomarkers detects fibrotic MASH
- Author
-
Sean Romeo, Connie Chan, Karen Matsukuma, Michael T. Corwin, Victoria Lyo, Shuai Chen, Guobao Wang, and Souvik Sarkar
- Subjects
Medicine ,Science - Abstract
Abstract Metabolic dysfunction-associated steatohepatitis (MASH) is a rising global disease signaling the urgent need for non-invasive tests (NITs). Recent work demonstrated that dynamic 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging can identify MASH by measuring liver glucose transport rate, K1, and liver CT attenuation. By combining dynamic PET/CT with the serum-based fibrosis-4 (FIB-4) test, we were able to better distinguish clinical MASH from fibrotic subtypes, enabling determination of the core tenets of MASH: steatosis, inflammation, and fibrosis. Future studies using FDG-PET technology can further enable concomitant prediction of MASH severity and extrahepatic comorbidities such as cardiovascular disease.
- Published
- 2024
- Full Text
- View/download PDF